Production (Stage)
Actuate Therapeutics, Inc.
ACTU
$10.33
$0.232.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.47% | 75.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.95% | 21.62% | |||
| Operating Income | 2.95% | -21.62% | |||
| Income Before Tax | 2.00% | -7.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.00% | -7.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.00% | -7.96% | |||
| EBIT | 2.95% | -21.62% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 1.73% | 40.52% | |||
| Normalized Basic EPS | 1.75% | 30.63% | |||
| EPS Diluted | 1.73% | 40.52% | |||
| Normalized Diluted EPS | 1.75% | 30.63% | |||
| Average Basic Shares Outstanding | -0.26% | 81.47% | |||
| Average Diluted Shares Outstanding | -0.26% | 81.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||